KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer

Ken Kato, Manish A. Shah, Peter Enzinger, Jaafar Bennouna, Lin Shen, Antoine Adenis, Jong Mu Sun, Byoung Chul Cho, Mustafa Özgüroǧlu, Takashi Kojima, Vladimir Kostorov, Cinta Hierro, Ying Zhu, Lee Anne McLean, Sukrut Shah, Toshihiko Doi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Treatment options for patients with advanced esophageal or esophagogastric junction (EGJ) cancer are limited. Current guidelines for first-line treatment of advanced esophageal or EGJ cancer recommend chemotherapy containing a platinum and a fluoropyrimidine agent. Pembrolizumab demonstrated antitumor activity in previously treated patients with advanced esophageal cancer and in patients with gastroesophageal junction cancer. Aim: To describe the design and rationale for the randomized, double-blind, placebo-controlled Phase III KEYNOTE-590 study, which will be conducted to investigate pembrolizumab in combination with chemotherapy as first-line treatment in patients with advanced esophageal or EGJ cancer. Clinical trial registry & ID: ClinicalTrials.gov: NCT03189719.

Original languageEnglish
Pages (from-to)1057-1066
Number of pages10
JournalFuture Oncology
Volume15
Issue number10
DOIs
Publication statusPublished - 2019 Apr

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kato, K., Shah, M. A., Enzinger, P., Bennouna, J., Shen, L., Adenis, A., Sun, J. M., Cho, B. C., Özgüroǧlu, M., Kojima, T., Kostorov, V., Hierro, C., Zhu, Y., McLean, L. A., Shah, S., & Doi, T. (2019). KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. Future Oncology, 15(10), 1057-1066. https://doi.org/10.2217/fon-2018-0609